TESS Research Foundation drives research for SLC13A5 Epilepsy, a recessive monogenic citrate transporter disorder, with seizures beginning soon after birth. Since 2015, TESS Research Foundation has gone from identifying the gene responsible for SLC13A5 Epilepsy to a gene therapy in development. Our strategy is to build a collaborative network of patients, doctors and researchers as we pursue near- and medium-term treatments. To date we have awarded more than $2 million dollars in direct research grants to more than 20 institutions around the world. We are research ready and eager to partner with you.
TESS Research Foundation drives research for SLC13A5 Epilepsy, a recessive monogenic citrate transporter disorder. Since 2015, TESS Research Foundation has gone from identifying the gene responsible for SLC13A5 Epilepsy to a gene therapy in development. To date we have awarded more than $2 million dollars in direct research grants to more than 20 institutions around the world. We are research ready and eager to partner with you.